FDA approves Genentech’s Avastin® (Bevacizumab)
Genentech announced the FDA has approved Avastin ® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer. December 06, 2016